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Background: Updated evidence-based guidelines for the management of atrial 
fibrillation (AF) necessitate patient review, particularly with respect to oral 
anticoagulants, to ensure maximum health gain around stroke prophylaxis. 
 
Objective: To quantify the level of anticoagulation utilisation in patients with a 
CHA2DS2-VASc ≥1/≥2 (male/female) according to evidence-based guidelines 
and to assess the impact of a pharmacist-led intervention to optimise therapy. 
 
Setting: Fifteen general medical practices in Liverpool, North-West England with 
a practice population of 99,129. 
 
Method: GRASP-AF software was employed to interrogate patient electronic 
medical records to identify and risk stratify AF patients (using CHA2DS2-VASc). 
A pharmacist then reviewed the medical records of those of patients not 
anticoagulated and with a CHA2DS2-VASc ≥1/≥2 (male/female). 
Recommendations were discussed with a general practitioner (GP) and those 
patients in whom the need for anticoagulation was agreed were invited for a 
consultation with either the pharmacist or GP and therapy optimised where 
appropriate. The GPs were responsible for managing those patients referred for 
diagnosis confirmation or further specialist opinion.  
 
Main outcome measures: Proportion of patients eligible/not eligible for 
anticoagulation; proportions in whom anticoagulants initiated, refused, 
antiplatelets discontinued. 
 
Results: Five hundred and twenty-three patients (31% of patients identified with 
AF and a CHA2DS2-VASc ≥1/≥2 (male/female)) were not receiving an 
anticoagulant (26 subsequently died or left the practice leaving 497). Three 
hundred and eighty-two (77%) pharmacist recommendations to a GP were 
agreed without modification. Following outcomes of diagnostic investigations and 
specialist referrals, 202 (41%) patients were candidates for anticoagulation, 251 
(51%) were not eligible for anticoagulation, 103 (21%) were anticoagulated (56 
warfarin, 47 DOAC).  
 
Conclusion: A pharmacist-led intervention re-aligned oral anticoagulant therapy 
to the latest evidence based guidelines for stroke prophylaxis, whilst 
simultaneously correcting the over-utilisation of antiplatelet therapy.  
 
Key words: Atrial fibrillation, pharmacist, stroke, anticoagulant 
 
Implication for practice 
 
• Pharmacists can have a major impact on increasing the uptake of oral 
anticoagulants in those with AF.  
• While patient consultations should embrace a shared decision making 
approach, a sizeable proportion of patients may still refuse oral anticoagulant 
treatment. 
• Practice models should be reviewed to ensure that patients are prescribed 
the evidence-based treatment from the point of diagnosis.  
 
Introduction Atrial fibrillation (AF) is the most commonly diagnosed 
arrhythmia, with a systematic review of 184 population-based studies providing 
an estimate of the global prevalence at around 33.5 million [1]. The burden of 
AF is great, being associated with a five-fold increase in the risk of stroke in 
those with non-valvular AF and a 17-fold increase in those with valvular-AF [2]. 
The prevalence of AF is predicted to rise significantly due to several factors 
including an aging population [3], and greater prevalence of hypertension, 
obesity and diabetes [4], leading to AF being labelled a ‘global epidemic’ [5,6]. 
While the risk of stroke can be managed effectively with oral anticoagulants, 
bleeding is a major drawback hence careful consideration of risks and benefits is 
required [7]. Stroke and bleeding risk are not homogenous in the population and 
must be calculated on an individual patient basis by using CHA2DS2-VASc 
(congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 
years [doubled], diabetes, stroke [doubled] - vascular disease, age 65-74 years, 
sex category [female])  and HASBLED (hypertension, abnormal renal/liver 
function, stroke, bleeding history or predisposition, labile INRs, elderly (age >65 
years), drugs/alcohol concomitantly) classifications which stratify risk based on 
the presence of co-morbidities [7].   
 
In recent years, three major developments have resulted in the necessity to 
update evidence-based guidance for the management of AF. Direct oral 
anticoagulants (DOACs) that are non-inferior to warfarin for AF stroke 
prophylaxis have been introduced to clinical practice [8-11]. Furthermore, the 
role of aspirin in AF related stroke prophylaxis is now in doubt with the 
emergence of evidence that oral anticoagulation is more effective [12-14]. 
Aspirin has also been shown to be ineffective compared to placebo or no therapy 
[15] with no overall net clinical benefit [16]. Recent evidence also suggests that 
anticoagulation should be considered at lower stroke risk levels than advised by 
previous guidance [17,18]. Such developments have led to the update of 
guidelines in 2010 from The European Society of Cardiology (ESC) and in 2014 
from The National Institute of Clinical Excellence (NICE) in England and Wales 
which now state that anticoagulation with warfarin or DOAC should be 
considered for patients with a CHA2DS2-VASc ≥1/≥2 (male/female) [7,19]. The 
current American Heart Association guidelines also advocate consideration of 
anticoagulation at a CHA2DS2-VASc ≥1 but do not distinguish between gender.  
 
Despite this plethora of evidence, it has been shown consistently that patient 
management in terms of the use of anticoagulants is suboptimal [20-23]. There 
is, however, a paucity of published literature describing approaches that have 
been adopted to address this shortfall. The Anticoagulant Programme East 
London, United Kingdom (UK) (APEL) was an improvement program conducted 
in three Clinical Commissioning Groups (CCGs, bodies which serve a specific 
geographical location with responsibility for commissioning healthcare services) 
[24]. Education, dedicated software and support were provided to medical 
practices to implement change, resulting in an increase in the proportion of 
patients being anticoagulated. The Primary Care Atrial Fibrillation (PCAF) service 
employed consultants to review AF patients in 56 UK medical practices 
(population 386,624) and initiate anticoagulation [25]. While several pharmacist 
led interventions aiming to improve management of AF have been described, 
these were all based in secondary care with small sample sizes [26-28]. To date, 
no published work describes a pharmacist led intervention in primary care in the 
UK. 
NHS England has embarked on an investment program that will see 1,970 
pharmacists practising clinically within medical practices by 2020 [29]. The 
General Practice Forward View report from NHS England states that 
“pharmacists remain one of the most underutilised professional resources in the 
system and we must bring their considerable skills in to play more fully” [29].  
 
Aims of the study  
The aims of the study were to quantify the level of anticoagulation utilisation in 
patients in primary care with a CHA2DS2-VASc ≥1/≥2 (male/female) according 
to NICE guidelines [19], and to assess the impact of a pharmacist-led 
intervention to optimise therapy. 
Ethical approval  
Ethical approval was obtained from the Research Ethics Panel of the School of 
Pharmacy and Life Sciences, Robert Gordon University, Scotland. Advice 
obtained from an NHS ethics committee indicated that approval was not 
required. Management approval to conduct the study was obtained from 













A clinical audit of practice against NICE guidelines [19], followed by pharmacist 
intervention to optimise anticoagulant prescribing. 
 
Setting 
The study was conducted in Liverpool, a major city in the North-West of 
England, which has a stroke mortality rate 20% greater in those less than 75 
years compared to patients in similar CCGs in England [30]. Sixty-one primary 
care medical practices participated in the study, which took place over a period 
of one year from February 2015. Prior to study commencement, an educational 
session covering the study aim and processes was delivered by the project lead 
to each medical practice.  
 
Inclusion and exclusion criteria 
Patients included had a history of any form of AF, a CHA2DS2-VASc ≥1/≥2 
(male/female) and were not prescribed an oral anticoagulant at the time of the 
study. There were no exclusions.  
Patient identification 
The GRASP-AF (Guidance on Risk Assessment and Stroke Prevention for Atrial 
Fibrillation) software, developed in partnership with NHS Improving Quality, was 
utilised to identify patients. The software scanned medical practice electronic 
records producing a list of patients with a documented diagnosis of AF and risk 
stratified patients according to CHA2DS2-VASc scores. Those with a CHA2DS2-
VASc ≥1/≥2 (male/female) not currently prescribed an oral anticoagulant were 
identified for further review.  
 
Patient review 
A team of medicines management staff were involved at various stages of the 
patient reviews, with training provided by the overall study lead to promote a 
consistent approach. Three pharmacists conducted the reviews independently, 
according to a standard operating procedure developed by the project lead, with 
support from the lead anticoagulant pharmacist, lead cardiovascular disease 
pharmacist and by the joint head of medicines management at LCH.  
 
The medical records of each patient were reviewed by a pharmacist to determine 
eligibility for anticoagulation. This included: determination of the validity of the 
AF diagnosis (confirmed by ECG); clinical course of AF since diagnosis; previous 
AF related therapy decisions, particularly exposure to anticoagulants (with 
reasons for any discontinuation) and patient refusal of anticoagulation (with 
reasons); relevant medical and social history; and presence of any 
contraindication or cautions to the use of anticoagulants.  A HASBLED score was 
calculated to quantify bleeding risk, based on which a recommendation was 
made by the pharmacist to the GP in terms of: possible candidate for 
anticoagulation; not suitable for anticoagulation; GP or specialist 
decision/investigation required; and diagnosis confirmation required. In addition, 
for patients prescribed antiplatelet therapy for lone AF (i.e. no other valid 
indication), the recommendation was made for them to attend their GP for an 
antiplatelet risk/benefit discussion.  
 
Patient reviews (including the CHA2DS2-VASc and HASBLED scores) and 
recommendations were documented on standard templates and presented to the 
GPs, either by email or paper-based, depending on the individual GP and medical 
practice preferences. Those recommendations which the GPs agreed were 
recorded in the patients’ electronic medical records using a standard template. A 
face-to-face discussion between GP and pharmacist was arranged to reach 
consensus on any non-agreed recommendations.  
 
Patient consultations 
Those patients in whom the decision to commence anticoagulation was agreed 
were invited by letter to make an appointment at the medical practice for a 
consultation with either the pharmacist or GP (depending on GP and medical 
practice preference). Domiciliary visits were arranged for housebound patients. 
The consultation focused on: individual stroke and bleeding risks (with or 
without anticoagulation); the poor risk/benefit of antiplatelets for stroke 
prevention (if relevant) [12-16]; and information on the available anticoagulant 
options to reduce stroke risk (including benefits and weaknesses). The NICE AF 
patient decision aid was a key tool utilised by pharmacists to ensure a shared 
decision making approach was employed [31]. Relevant scientific information 
was provided in a patient oriented manner (e.g. pictorial representations of 
stroke and bleeding risk) whilst also taking into account patient values and 
preferences [32]. A record of the outcome of the consultation (patient 
agreement or not with the recommendation) was recorded in the electronic 
medical record.  
Those patients opting for warfarin were referred directly to the anticoagulant 
service for counselling and initiation. Patients electing a DOAC were referred for 
baseline blood tests (urea and electrolytes, liver functions tests and full blood 
count), following which they were invited back for counselling and initiation 
(blood results permitting). The GPs were responsible for the management of 
those patients requiring investigations (e.g. ECGs) or specialist input. Medical 
practices were revisited by a member of the research team after four and six 
months to ensure that recommendations (e.g. specialist advice sought) had 
been actioned. 
 
The study flowchart is provided in Figure 1.  
 
Data analysis 
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Figure 1. Study flowchart 
Run GRASP-AF 
Results 
From a combined practice population of 99,129, a study population of 497 was 
















Figure 2. Derivation of study population 
1,753 patients 
CHA2DS2-VASc ≥1 
1,865 patients identified 
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The mean age of the study population was 75.5 (standard deviation, SD 11.9) 
years with 291 (58.6%) male. The mean CHA2DS2-VASc score was 3.32 (SD 1.6) 
with almost one quarter (23.9%) at score 3 and one fifth (20.1%) at score 4. 
One hundred and seventy (34.2%) patients had previously been on an 
anticoagulant and 61 (12.2%) patients had previously declined an anticoagulant. 
















Following pharmacist review of the medical notes, patients were categorised into 






































































































The GPs agreed with 382 (76.9%) of recommendations without modification, 
with the major area of disagreement being in relation to those patients referred 
by the pharmacist to the GP for their opinion, further investigation or specialist 
input. Following pharmacist and GP input, 171 (34.4%) patients were identified 
as candidates for anticoagulation, 181 (36.4%) were not suitable for 
anticoagulation (142 contraindicated, 39 not indicated), 79 (15.9%) required 
further investigation or specialist input, 32 (6.4%) required confirmation of 
diagnosis and 34 (6.8%) required regular monitoring of pulse and AF symptoms. 
One hundred and eleven patients were investigated further (e.g. ECGs, referral 
to specialists), following which 31 patients were deemed suitable for 
anticoagulation giving a total of 202 (40.6%) patients for anticoagulation.  
 
Patients deemed suitable for anticoagulation 
Average patient age was 75.8 (SD 10.9) years, with 115 (56.9%) male and a 
mean CHA2DS2-VASc of 3.4 (SD 1.5). Of these 202 patients, 103 (51.0%) 
commenced an anticoagulant (59 at GP consultation and 44 at pharmacist 
consultation); 85 (83.3%) were switched from antiplatelet to anticoagulant. 
Fifty-six patients (54.4%) commencing an anticoagulant opted for warfarin and 
the others DOAC treatment. A further 76 (37.6%) refused anticoagulation (45 
GP consultation, 31 pharmacist consultation), 16 (7.9%) failed to attend and 7 
(3.5%) commenced an anticoagulant in secondary care.  
 
Of 49 candidates for anticoagulation who had previously declined 
anticoagulation, 23 (46.9%) agreed to commence treatment, with the remainder 
refusing.  
Patients not suitable for anticoagulation 
One hundred and sixty-five patients were deemed unsuitable for anticoagulation 
(see Table 1), with the majority of patients (135, 81.8%) having multiple 
contraindications.   











Poor prognosis - e.g. palliative, advanced malignancy. 19 11.5 
Significant renal or hepatic disease. 15 9.1 
History of serious bleed - e.g. subarachnoid haemorrhage, 
Haemorrhagic stroke, GI bleed/haemorrhage. 38 23.0 
Gastrointestinal (GI) disease - e.g. inflammatory bowel 
disease, GI ulceration, varices. 39 23.6 
Haematological abnormalities - e.g. anaemia, coagulopathies, 
myelodysplasia. 25 15.2 
Central nervous system disease - e.g. dementia, epilepsy, 
paranoid psychosis. 47 28.5 
As advised by secondary care  23 13.9 
Miscellaneous contraindications e.g. injurious falls, poor 
compliance, alcohol dependence. 67 40.6 
Discussion 
This study demonstrated that oral anticoagulation for the management of AF 
could be optimised as a direct result of a pharmacist-led intervention in primary 
care. There was a high level of GP agreement with the pharmacist 
recommendations and indeed the GPs viewed that even more patients should be 
anticoagulated when referred by the pharmacists for further investigation. Many 
patients could not receive anticoagulants due to one or more contraindication 
and a number were reluctant to commence an anticoagulant. Of all patients with 
CHA2DS2-VASc ≥1/≥2 (male/female), this study resulted a 6% increase in 
anticoagulant prescribing.  
 
There is overwhelming evidence that optimising the management of AF through 
anticoagulant prescribing will lead to a marked decrease in stroke prevalence. 
While estimations in the literature are derived from studies of warfarin, DOACs 
are non-inferior to warfarin [8-11] and modelling data suggests a lower number 
needed to treat for DOACs [33,25]. Using study findings and warfarin based 
figures, the interventions implemented in this study are estimated to have 
averted 3.78 stokes/year and 29.1 strokes over a lifetime (0.039 strokes/year 
and 0.30 over a lifetime averted/person anticoagulated) [34]. These estimates 
must be interpreted with caution as they assume patient adherence, although 
the shared decision making approach employed should have had a positive 
impact on patient adherence [35]. 
   
Patient anticoagulation refusal rates were similar (approximately 40%) for both 
pharmacists and GPs, despite the implementation of a shared decision making 
approach. While these refusals rates are similar to other studies employing the 
same approach [37,38,39], this is still worrying given the evidence of benefit 
which these patients are not deriving. One limitation of this study is that no data 
were collected on reasons for refusal. However, qualitative studies provide the 
following explanations: patient perception of increased bleeding risk; individual 
patient preferences; personally held beliefs [37,38,40]; feeling unable to make a 
judgement; reluctance to change therapy [40]; and aversions to taking 
medication [41]. There is also limited evidence that shared decision making may 
lead to more conservative decision making [42], with some patients expressing 
a desire to leave the final decision to the practitioner [43].  Refusal rates may 
have been influenced by perceptions of warfarin and it being labelled as a ‘rat 
poison’. In a randomised trial of AF thromboprophylaxis, 36% of patients 
changed their original decision to be treated with a blinded drug once the name 
had been unblinded as warfarin [44]. While some claim that optimal patient care 
will be achieved when evidence based medicine and shared decision making are 
combined [45], others suggest that performance measures should focus on the 
proportion of eligible patients participating in shared decision making rather than 
on the uptake of medication [46]. 
 
Our study adds to the evidence base around beneficial effects of pharmacists 
working in general medical practices care, complementing other studies 
demonstrating: identification of high risk patients and improved disease 
management [47]; and increased evidence based prescribing [48]. In a 
systematic review of 38 studies examining the effectiveness of clinical 
pharmacists in a primary care, pharmacist input was shown to be favourable in 
chronic disease management and quality use of medicines [49].  This evidence 
base helps provide justification for the investment into primary care pharmacists 
by NHS England.  
 
While this study optimised anticoagulation retrospectively, practice should also 
be remodelled to ensure that patients receive the most appropriate evidence-
based therapy at the time of diagnosis rather than having to be corrected at a 
later stage.  
 
To our knowledge, this is the first study which reports a primary care pharmacist 
led intervention in the management of patients with AF in the UK. There are, 
however, limitations hence the study should be interpreted with caution. The 
study was conducted in 15 medical practices in one city of the UK hence the 
results may not be generalisable to other practices in the UK and beyond, 
particularly those settings with major differences in healthcare structures and 
processes. There was limited follow-up of patients to determine persistence and 
adherence with oral anticoagulants and no measures of impact on health 
outcomes. Furthermore, no economic evaluation was included in the study.  
 
Future research could extend this study to include pharmacist independent 
prescribers who could change and commence therapy without the need for 
further GP input [50,51].  There is need to explore patient perceptions and 




A pharmacist-led intervention realigned oral anticoagulant therapy to the latest 
evidence based guidelines for stroke prophylaxis, whilst simultaneously 
correcting the over-utilisation of antiplatelet therapy. There, however, remains a 
need to consider those patients in whom anticoagulants are contraindicated and 
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